ANGO Earning Date, Transcript Summary & Report

Earnings Surprise Achieved: AngioDynamics, Inc. beats earnings expectations with reported EPS of $0.03, exceeding expectations of $-0.13.

Worldwide Revenue Growth: Total worldwide revenue reached $72 million, representing over 9% year-over-year growth.

MedTech Segment Growth: The MedTech segment experienced significant growth of 22%, driven by strong performance across all platforms.

Product Line Revenue Growth: Auryon product line grew approximately 17% year-over-year, showcasing consistent revenue growth.

Mechanical Thrombectomy Growth: Mechanical Thrombectomy products, including AlphaVac and AngioVac, saw a combined growth of approximately 47% over the previous year.

Strong Revenue Growth: AlphaVac revenue increased by over 160%, indicating strong adoption for treating pulmonary embolism.

AngioVac Revenue Growth: AngioVac contributed $6.8 million in revenue, representing a 23% growth over the prior year period.

NanoKnife Revenue Growth: NanoKnife revenue grew by 5.3%, with disposable revenue increasing by 16.2%, indicating positive trends in adoption.

Gross Margin Improvement: Gross margin improved to 54%, an increase of 290 basis points compared to the previous year, reflecting operational efficiency.

EBITDA Improvement: Adjusted EBITDA was reported at $1.3 million, a significant improvement from a loss of $3.6 million in the prior year.

Fiscal 2025 Revenue Guidance: The company increased its guidance for fiscal 2025, expecting revenue in the range of $285 million to $288 million, representing growth of 5.3% to 6.4%.

MedTech Sales Growth Update: MedTech net sales are now expected to grow between 14% to 16%, ahead of previous guidance.

Adjusted EBITDA Increase: Adjusted EBITDA guidance was raised to a range of $4 million to $5 million, up from $1 million to $3 million.

Adjusted EPS Loss Improvement: Adjusted EPS was a loss of $0.08 per share, improving from a loss of $0.16 per share in fiscal 2024, indicating ongoing challenges in achieving profitability.

Med Device Revenue Stagnation: Med Device segment revenue increased only 1% over last year, suggesting stagnation in this area compared to the more robust growth in MedTech.

Capital Sales Decline: Capital sales for NanoKnife are expected to be approximately half of what they were in 2024, indicating a significant decline in this revenue stream.

Cash Flow Challenges: The company utilized $13.2 million in operating cash during the quarter, indicating cash flow challenges despite overall revenue growth.

Financial Struggles Persist: The adjusted net loss was $3.1 million, highlighting ongoing financial struggles despite improvements in revenue and operating leverage.

Tariff Impact Monitoring: The company is closely monitoring potential tariffs, which could impact future costs and profitability, although they currently do not expect a material impact.

Cash Utilization Strain: The transition manufacturing arrangement with Spectrum Vascular has led to cash utilization of approximately $10 million, indicating financial strain during this transition period.